In this project, we aim to validate a Home Hospitalization plan for patients with TIA or minor stroke. Our hypothesis is that our Multimodal Home Hospitalization program (NORAHOME) for patients with TIA and minor stroke is safe, reduces the complications associated with conventional hospitalization, and is more efficient than Standard Clinical Practice. To conduct the study, we require the voluntary participation of patients with TIA and minor strokes.
Age >18 years.
Availability of a smartphone for the patient or caregiver.
Family support and/or formal caregiver.
Clinical stability during the last 12 hours in the Emergency Department.
Severe stenosis or symptomatic arterial occlusion requiring admission for potential reperfusion and/or arterial revascularization treatments.
Patients with pre-existing neurological or psychiatric conditions that may interfere with or complicate follow-up and evaluations.
Clinical (terminal condition) or social (language barrier) impossibility to complete follow-up assessments.
Parallel
Home hospitalization
Other interventionpatients randomized to the treatment group (NORAHOME) to validate that our Home Hospitalization program for patients with TIA or minor stroke
Primary efficacy objective
Change in the rate of early recurrence and hospital readmission compared to standard clinical practice.
Primary efficacy objective
Change in the rate of early recurrence and hospital readmission compared to standard clinical practice.
Primary safety objective
Change in the number of complications (falls, recurrences, infections) in patients with TIA/minor stroke compared to standard clinical practice.
Effectiveness
Change in direct hospital costs compared to standard clinical practice.
Security
Change in the incidence of complications associated with hospital admission (delirium, nosocomial infections, falls).
Patient reported outcomes
Change in patient-reported health outcomes (PROMs) and patient experience measures (PREMs) compared to standard clinical practice
Patient information
Change in patient knowledge about stroke and key secondary prevention recommendations after the acute stroke phase.
Click on the lead sponsor to view all of their trials.
Hospital Universitari Vall d'Hebron Research Institute
Lead sponsor
Vall Hebron Insitut Recerca
Collaborator
Hospital Vall d'Hebron
Collaborator
